Who we are
Building on a platform of global success, Fresenius Kabi is launching a new Canadian biosimilars division. Our entry into this space follows the 2017 acquisition of a biosimilar business, including its entire development pipeline and an experienced team of employees. We have a number of biosimilar products in development focusing on autoimmune diseases, with the first scheduled to launch in early 2021.
With over 20 years of excellence in biologic manufacturing at a Swiss facility, we are committed to upholding the same quality standards in developing and producing biosimilars as the originator biologics while supporting the unique needs of patients, practitioners and the Canadian healthcare system.
What makes us different
We believe healthcare should never be “one size fits all”, and the launch of our biosimilars division brings new opportunities to create powerful customer partnerships. That’s why we offer an individualized approach to help address the unique needs of Canadian patients and the healthcare system as a whole.
We have built an agile and diverse team in Canada that’s backed by extensive expertise in biosimilars, and we are ready to channel our skills and resources into helping more patients access effective treatments than ever before. These qualities make us a true partner to the healthcare system; we work closely with healthcare professionals, payers and patients to develop value-added services that improve patient care.
But that’s not all.
At Fresenius Kabi, we recognize our responsibility to supporting the sustainability of Canada’s healthcare system and the public purse. We ensure our efforts always keep an eye on the big picture when it comes to improving patient care and respecting the nuances of the healthcare system.
We are committed to the effective and safe treatment of our patients, through painstaking detail and state-of-the-art analysis to ensure these goals are met
Biosimilars - what are they? Learn here